Literature DB >> 18825135

A case of macrophage activation syndrome successfully treated with anakinra.

Alison Kelly1, Athimalaipet V Ramanan.   

Abstract

BACKGROUND: A 13-year-old girl presented with features typical of systemic juvenile idiopathic arthritis, including fever, rash and arthritis. Her past medical history was unremarkable. INVESTIGATIONS: Routine investigations, including CBC, serological tests for urea and electrolyte levels, tests of liver function and clotting, measurement of erythrocyte sedimentation rate, cultures of blood, urine and throat swabs, abdominal ultrasonography, echocardiography, bone marrow aspiration, and determination of laboratory parameters, including presence of anti-streptolysin O antibody and levels of C-reactive protein, lactate dehydrogenase, serum ferritin, D-dimer, fibrinogen and ciclosporin. Specialized investigations included measurement of serum levels of interleukin (IL)-1, IL-6, IL-10, tumor necrosis factor and soluble CD25. DIAGNOSIS: Systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome. MANAGEMENT: The disease remained active following treatment with intravenous steroid, immunoglobulin and ciclosporin. The patient's disease was successfully controlled following the introduction of anakinra.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18825135     DOI: 10.1038/ncprheum0919

Source DB:  PubMed          Journal:  Nat Clin Pract Rheumatol        ISSN: 1745-8382


  48 in total

Review 1.  IL-1 pathways in inflammation and human diseases.

Authors:  Cem Gabay; Céline Lamacchia; Gaby Palmer
Journal:  Nat Rev Rheumatol       Date:  2010-02-23       Impact factor: 20.543

Review 2.  Macrophage activation syndrome complicating rheumatic diseases in adults: case-based review.

Authors:  Mayan Gilboa; Gil Bornstein; Ilan Ben-Zvi; Chagai Grossman
Journal:  Rheumatol Int       Date:  2019-07-31       Impact factor: 2.631

3.  Adult-Onset Still's Disease and Macrophage-Activating Syndrome Progressing to Lymphoma: A Clinical Pathology Conference Held by the Division of Rheumatology at Hospital for Special Surgery.

Authors:  Bella Mehta; Shanthini Kasturi; Julie Teruya-Feldstein; Steven Horwitz; Anne R Bass; Doruk Erkan
Journal:  HSS J       Date:  2018-03-26

4.  [Macrophage activation syndrome].

Authors:  P Lehmann; E Huber; T Dörner; M Fleck
Journal:  Z Rheumatol       Date:  2012-10       Impact factor: 1.372

Review 5.  Caspase functions in cell death and disease.

Authors:  David R McIlwain; Thorsten Berger; Tak W Mak
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-04-01       Impact factor: 10.005

6.  Plasma exchange, methylprednisolone, IV immune globulin, and now anakinra support continued PICU equipoise in management of hyperferritinemia-associated sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome/secondary hemophagocytic lymphohistiocytosis syndrome*.

Authors:  Dennis W Simon; Rajesh Aneja; Joseph A Carcillo; E Scott Halstead
Journal:  Pediatr Crit Care Med       Date:  2014-06       Impact factor: 3.624

Review 7.  Biologics in juvenile idiopathic arthritis: a narrative review.

Authors:  Federica Vanoni; Francesca Minoia; Clara Malattia
Journal:  Eur J Pediatr       Date:  2017-07-20       Impact factor: 3.183

8.  2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.

Authors:  Sarah Ringold; Pamela F Weiss; Timothy Beukelman; Esi Morgan DeWitt; Norman T Ilowite; Yukiko Kimura; Ronald M Laxer; Daniel J Lovell; Peter A Nigrovic; Angela Byun Robinson; Richard K Vehe
Journal:  Arthritis Rheum       Date:  2013-10

9.  Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist.

Authors:  Scott Canna; Jennifer Frankovich; Gloria Higgins; Michael R Narkewicz; S Russell Nash; J Roger Hollister; Jennifer B Soep; Leonard L Dragone
Journal:  Pediatr Rheumatol Online J       Date:  2009-12-22       Impact factor: 3.054

Review 10.  Why not treat human cancer with interleukin-1 blockade?

Authors:  Charles A Dinarello
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.